News In brief BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7470.816 (Published 07 October 2004) Cite this as: BMJ 2004;329:816 Article Related content Metrics Responses Peer review Related articles Editorial Selective serotonin reuptake inhibitors Published: 07 October 2004; BMJ 329 doi:10.1136/bmj.329.7470.809 News Merck chief quits as further material on Vioxx emerges Published: 12 May 2005; BMJ 330 doi:10.1136/bmj.330.7500.1101-a News Court awards claimant $13.5m in rofecoxib lawsuit Published: 20 April 2006; BMJ 332 doi:10.1136/bmj.332.7547.927-a News Journal criticises Vioxx study for omitting three heart attacks Published: 15 December 2005; BMJ 331 doi:10.1136/bmj.331.7530.1423 Letter Patients' interests: paramount in randomised trials Published: 30 December 2004; BMJ 330 doi:10.1136/bmj.330.7481.44-a See more Maternal deaths from suicide must be tackled, say experts BMJ December 07, 2016, 355 i6585; DOI: https://doi.org/10.1136/bmj.i6585 Andrew Wakefield calls Trump “on our side” over vaccines after meeting BMJ December 05, 2016, 355 i6545; DOI: https://doi.org/10.1136/bmj.i6545 The future of NHS dentistry in Scotland BMJ December 05, 2016, 355 i6466; DOI: https://doi.org/10.1136/bmj.i6466 South Africa begins first HIV vaccine trial in seven years BMJ December 01, 2016, 355 i6501; DOI: https://doi.org/10.1136/bmj.i6501 Better evidence for smarter policy making BMJ December 01, 2016, 355 i6399; DOI: https://doi.org/10.1136/bmj.i6399